xanthinol niacinate has been researched along with bezafibrate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Djaja, S; Machalke, K; Richter, E | 1 |
| Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG | 2 |
1 trial(s) available for xanthinol niacinate and bezafibrate
| Article | Year |
|---|---|
[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Theophylline; Xanthinol Niacinate | 1982 |
3 other study(ies) available for xanthinol niacinate and bezafibrate
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
Topics: Adolescent; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Inositol; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Nicotinic Acids; Nicotinyl Alcohol; Xanthinol Niacinate | 1980 |
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Inositol; Lipoproteins; Nicotinic Acids; Xanthinol Niacinate | 1980 |